NCT00077870View on ClinicalTrials.gov

A Study to Evaluate the Safety of Escalating Doses of Ocrelizumab in Subjects With Rheumatoid Arthritis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

237

Participants

Timeline

Start Date

February 29, 2004

Study Completion Date

December 31, 2006

Conditions
Rheumatoid Arthritis
Interventions
DRUG

ocrelizumab

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY